AIRLINK 74.64 Decreased By ▼ -0.21 (-0.28%)
BOP 5.01 Increased By ▲ 0.03 (0.6%)
CNERGY 4.51 Increased By ▲ 0.02 (0.45%)
DFML 42.44 Increased By ▲ 2.44 (6.1%)
DGKC 87.02 Increased By ▲ 0.67 (0.78%)
FCCL 21.58 Increased By ▲ 0.22 (1.03%)
FFBL 33.54 Decreased By ▼ -0.31 (-0.92%)
FFL 9.66 Decreased By ▼ -0.06 (-0.62%)
GGL 10.43 Decreased By ▼ -0.02 (-0.19%)
HBL 114.29 Increased By ▲ 1.55 (1.37%)
HUBC 139.94 Increased By ▲ 2.50 (1.82%)
HUMNL 12.25 Increased By ▲ 0.83 (7.27%)
KEL 5.21 Decreased By ▼ -0.07 (-1.33%)
KOSM 4.50 Decreased By ▼ -0.13 (-2.81%)
MLCF 38.09 Increased By ▲ 0.29 (0.77%)
OGDC 139.16 Decreased By ▼ -0.34 (-0.24%)
PAEL 25.87 Increased By ▲ 0.26 (1.02%)
PIAA 22.20 Increased By ▲ 1.52 (7.35%)
PIBTL 6.80 No Change ▼ 0.00 (0%)
PPL 123.58 Increased By ▲ 1.38 (1.13%)
PRL 26.81 Increased By ▲ 0.23 (0.87%)
PTC 14.01 Decreased By ▼ -0.04 (-0.28%)
SEARL 58.53 Decreased By ▼ -0.45 (-0.76%)
SNGP 68.01 Decreased By ▼ -0.94 (-1.36%)
SSGC 10.47 Increased By ▲ 0.17 (1.65%)
TELE 8.39 Increased By ▲ 0.01 (0.12%)
TPLP 11.05 Decreased By ▼ -0.01 (-0.09%)
TRG 63.21 Decreased By ▼ -0.98 (-1.53%)
UNITY 26.59 Increased By ▲ 0.04 (0.15%)
WTL 1.42 Decreased By ▼ -0.03 (-2.07%)
BR100 7,941 Increased By 103.5 (1.32%)
BR30 25,648 Increased By 196 (0.77%)
KSE100 75,983 Increased By 868.6 (1.16%)
KSE30 24,445 Increased By 330.8 (1.37%)

A new clinical trial evaluating the efficacy and safety of plasma therapy, an emerging form of treatment for the Covid-19, in Pakistan is underway at Aga Khan University.

Convalescent plasma therapy involves separating blood donated by cured Covid-19 patients into plasma: a clear straw-coloured liquid that contains antibodies and proteins that helps fighting infections. The plasma is then injected into a severely ill Covid-19 patient with powerless immune system to generate the antibodies needed to combat the virus. A single donation can potentially treat two patients.

There is currently no vaccine for the Covid-19 virus and no approved form of treatment beyond managing its symptoms. The trial will generate evidence on whether plasma therapy, the only experimental treatment currently available for the virus, can help treat patients suffering from acute complications from the virus.

Researchers will perform three pre-procedural investigations on each donor to ensure their blood is safe from other infections and to check their suitability for the process of apheresis which collects plasma. Like a typical blood donation, the process is painless after the initial prick and lasts approximately two hours.

Once plasma is transfused into a patient, the team will monitor the response to the treatment and assess its effectiveness through clinical and laboratory tests. Informed consent will be sought from all potential donors as well as those receiving the treatment.

"Plasma therapy can potentially help treat patients with moderate to severe Covid-19 infection," said Dr Natasha Ali, who is part of a team of six faculty members from the departments of Pathology and Laboratory Medicine, and Internal Medicine, working on the trial. "This trial is a part of the varsity's science-based approach to evaluating novel treatments that can help save lives during this pandemic."

The university is also participating in 'Solidarity,' the international clinical trial launched by the World Health Organization and its partners, to find effective treatments for the coronavirus.

The study has been approved by the Drug Regulatory Authority of Pakistan and Pakistan's National Bioethics Committee.

Copyright Business Recorder, 2020

Comments

Comments are closed.